Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1983 Aug;24(2):293–296. doi: 10.1128/aac.24.2.293

Antimicrobial activity and other in vitro properties of cefoperazone A, the principal metabolite of cefoperazone sodium.

R N Jones, A L Barry
PMCID: PMC185156  PMID: 6638991

Abstract

Cefoperazone A, the principal metabolite of cefoperazone, was found to have an antimicrobial activity ranging from slightly below to 16-fold less than that of the parent drug. Like cefoperazone, the metabolite is bactericidal, penetrates well into bacterial cells, and has moderate beta-lactamase stability, some strains of members of the family Enterobacteriaceae produce an inoculum effect on the metabolite activity.

Full text

PDF
293

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ayers L. W., Jones R. N., Barry A. L., Thornsberry C., Fuchs P. C., Gavan T. L., Gerlach E. H., Sommers H. M. Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing. Antimicrob Agents Chemother. 1982 Nov;22(5):859–877. doi: 10.1128/aac.22.5.859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brogden R. N., Carmine A., Heel R. C., Morley P. A., Speight T. M., Avery G. S. Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy. Drugs. 1981 Dec;22(6):423–460. doi: 10.2165/00003495-198122060-00002. [DOI] [PubMed] [Google Scholar]
  3. Jones R. N., Barry A. L. Cefoperazone: a review of its antimicrobial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics. Rev Infect Dis. 1983 Mar-Apr;5 (Suppl 1):S108–S126. doi: 10.1093/clinids/5.supplement_1.s108. [DOI] [PubMed] [Google Scholar]
  4. Jones R. N., Barry A. L., Thornsberry C. Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy. Rev Infect Dis. 1982 Sep-Oct;4 (Suppl):S366–S373. doi: 10.1093/clinids/4.supplement_2.s366. [DOI] [PubMed] [Google Scholar]
  5. Mashimo K. Clinical experience with cefoperazone in biliary tract infections. Drugs. 1981;22 (Suppl 1):100–107. doi: 10.2165/00003495-198100221-00021. [DOI] [PubMed] [Google Scholar]
  6. Nakamura T., Hashimoto I., Sawada Y., Mikami J., Bekki E., Hirasawa S., Abe H., Watanabe Y. Cefoperazone concentrations in bile and gall bladder wall after intravenous administration. Antimicrob Agents Chemother. 1980 Dec;18(6):980–982. doi: 10.1128/aac.18.6.980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Shimizu K. Cefoperazone: absorption, excretion, distribution, and metabolism. Clin Ther. 1980;3(Spec Issue):60–79. [PubMed] [Google Scholar]
  8. Wright W. E., Line V. D. Biliary excretion of cephalosporins in rats: influence of molecular weight. Antimicrob Agents Chemother. 1980 May;17(5):842–846. doi: 10.1128/aac.17.5.842. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES